Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
agreed. govt shut down or not, im glad its october now.
im ready for the flop, the turn, and the river. we are all tired of our two card hands.
Amen my friend!
Zip,
i don't think that is a stretch that's why so many of us longs have endured the amrn journey for what seems like years. Myself 3+ years- my dilemma of course was adding at the wrong times so now we stiffen and wait:) vascepa works, millions will be better off by using it and it has a safety profile of a placebo which should be worth billions down the road ....
thanks for passing that along ..
so we disagree :)
attm,
exactly this drug has to replace lovaza over time the safety profile dictates this imo
AJ,
yup on most of it ... though i'm not sure more DD goes into a short position as i think history validates being short is more profitable in a start up biotech. This stock has me scratching my head as this is what i do for a living and my wife has heard me utter 'what am i missing' more than once after the opening/closing bell :).
YB,
I tend to agree with you... there are a lot of unresolved issues with AMRN none of which are efficacy and safety which is a great thing... for JZ or the board to maximize shareholder value the resolution of most of these issues surrounds GIA, partnering or BO obviously anchor needs FDA approval. What I underestimated was the response time prescribers have to a 'better mousetrap' scary that lovaza is still drug of choice with a-fib warning and a rise in LDL. Marketing 101- you can have a better mousetrap but if nobody knows about it-it won't matter.
Zum,
I concur the safety profile of Vascepa is such that it is worth a shot and as a prescriber i can sleep at night
promise:)
Agreed
and in fact don't prescribe meds to lower them ... rather changes in diet and exercise only )
unfortunately a lot of people don't adhere to that recommendation
Study, well done! i just finished listening to the presso and then clicked on your synopsis. I keep wondering if 2gm is good and 4gm is better is 6gm best? I liked John's response to what if Anchor indication is not approved - he thoroughly expects approval and why wouldn't he? it's effective for the indication and placebo safe. The next few months should be easier for the longs than obviously the last several months :) Reduce-it theoretically should be successful as well and then we are in blockbuster territory imo. I could be wrong but i own 50k+ shares that i believe will validate my DD ...
i wondered the same and i think JL commented that a key thought leader in the CV or lipid space believed 6 was ideal? i don't know if amrn would run into supply issues if this becomes a maintenance drug for millions globally ... what a nice problem to have as a shareholder :)
yup,
It's one of the best therapuetic drugs on the mkt nobody knows about:) Communicating the value of Vascepa is job ONE moving forward. "It works and it's safe" shouldn't be too much of a stretch to prescribe it based on the philosophy of first do no harm and SWAN- sleep well at night. You can't do this with 300 reps....
which begs the question- if 4gm's is effective is 6 gm's more so?
It's like preaching to the choir here :). Lovaza still being prescribed after links to a-fib and a best in class alternative now available? I've been long prior to phase 3 and have added generously and at times erroneously over the years. Early this week i purchased another $50k worth. I have done my DD thanks in part to many of you reading this :) Vascepa is the best drug nobody knows about, yet.... and it's the yet i'm waiting for :) The EPA/AA ratio information is HUGE. As an investor, i'm always looking for reasons why I shouldn't own a particular stock with AMRN I'm now asking myself why I'm not taking Vascepa prophylatically?
i think we longs would be foolish to think it couldn't get worse before it gets better ... let me be your barometer- i have purchased in the 15's, 13's, 12's,10's, own some in the 9's, of course the 7's remember when that was the bottom? increased my margin balance in the 6's and recently purchased 50k bucks worth in the 5's .. so i smell your cookin' yellow bluff :) have a great weekend folks and i would say "here is to good scripts #'s" but that doesn't seem to be the answer at this point ...but always REMEMBER it works and it is safe
excellent safety and efficacy profile
Bingo! the safety profile of a placebo allows a doc ' to first do no harm' aka sleep well at night :)
I spoke wednesday with my cardio doc friend in mesa, az and he has not been contacted in fact he didn't know Vascepa was on the market
Thx :)
Having blood work done .. what do you suggest I have measured in the inflammation area CRP, apoB and c? anything else?
Meanwhile, Dublin -based Omthera-rival Amarin Corp. (AMRN) slipped 5.8% to $ 6.39 . Citi said investors should be buying the biotech in the wake of the selloff prompted by AstraZeneca's (AZN) planned takeover of AMRN rival Omthera ( OMTH). Citi said that a more-meaningful takeaway "is the positive indication this deal reflects on future utility for" cardiovascular omega-3 drugs, like Amarin's Vascepa.
What will be revealed in a peer review journal is that it was quite possible adenoma's under 1 cm were categorized as 1 cm or larger ... the larger the adenoma the more sDNA shed. Also the advanced age of some of the 10k in the study may have affected specifity. Again, the test detected 66% of the 2cm adenoma's the ones with a 46% chance of turning into CRC ... progammatic testing insures this eradicates CRC in the screening population. The smaller adenomas (1 cm or less) rarely turn bad and the good news is you have perhaps up to 10 years before they do as they grow they shed more dna into the stool. The peer review should shed light on left side v right side detection huge news for the hard to see serrated lesions commonly found on left side.
Economically, you would rather not send someone to colo for a very small polyp assuming that person is screened every three years. A lot of misinformation out there hence the dramatic drop in price wait and see what is revealed in the review journal.